Bio-Techne Beheer
Beheer criteriumcontroles 2/4
De CEO Bio-Techne is Kim Kelderman, benoemd in Feb2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.85M, bestaande uit 11.1% salaris en 88.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde $ 3.03M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 7.8 jaar.
Belangrijke informatie
Kim Kelderman
Algemeen directeur
US$6.9m
Totale compensatie
| Percentage CEO-salaris | 11.1% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 0.03% |
| Management gemiddelde ambtstermijn | 1.3yrs |
| Gemiddelde ambtstermijn bestuur | 7.8yrs |
Recente managementupdates
Recent updates
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Sep 26
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching
Sep 11Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings
Aug 24When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$151m |
| Jun 30 2024 | US$7m | US$760k | US$168m |
| Mar 31 2024 | n/a | n/a | US$203m |
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
| Mar 31 2019 | n/a | n/a | US$121m |
| Dec 31 2018 | n/a | n/a | US$96m |
| Sep 30 2018 | n/a | n/a | US$128m |
| Jun 30 2018 | US$2m | US$73k | US$126m |
Compensatie versus markt: De totale vergoeding ($USD 6.85M ) Kim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.88M ).
Compensatie versus inkomsten: De beloning van Kim is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Kim Kelderman (57 yo)
less than a year
Tenure
US$6,852,495
Compensatie
Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$6.85m | 0.025% $ 3.0m | |
| Executive VP of Finance & CFO | 10.6yrs | US$5.20m | 0.063% $ 7.6m | |
| Senior VP | 1.7yrs | US$1.46m | 0.0011% $ 127.7k | |
| President of Protein Sciences Segment | 2.8yrs | US$3.65m | 0.0028% $ 337.2k | |
| President of Diagnostics & Genomics | less than a year | US$2.27m | geen gegevens | |
| VP & CTO | less than a year | geen gegevens | geen gegevens | |
| Senior Director of Investor Relations & Corporate Development | no data | geen gegevens | geen gegevens | |
| Vice President of Sales and Marketing | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Strategy & Corporate Development | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Chief Human Resources Officer | less than a year | geen gegevens | geen gegevens | |
| Managing Director | 8.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Analytical Solutions Division | 1.8yrs | geen gegevens | geen gegevens |
1.3yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TECH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$6.85m | 0.025% $ 3.0m | |
| Independent Chairman of the Board | 21.8yrs | US$410.46k | 0.028% $ 3.4m | |
| Independent Director | 15.5yrs | US$300.46k | 0.030% $ 3.7m | |
| Independent Director | 7.8yrs | US$275.46k | 0.0087% $ 1.0m | |
| Independent Director | 14.5yrs | US$290.46k | 0.028% $ 3.4m | |
| Independent Director | 4.3yrs | US$291.50k | 0.0045% $ 541.9k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.4yrs | US$275.46k | 0.0059% $ 709.3k | |
| Independent Director | 7.8yrs | US$275.46k | 0.0087% $ 1.0m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | less than a year | US$113.73k | 0.0014% $ 162.6k |
7.8yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TECH wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).